Celcuity Inc. (CELC) Q3 2025 10-Q Quarterly Report
Celcuity Inc. (CELC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Celcuity Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: increased tariffs and trade policy uncertainty due to U.S. changes triggering retaliatory foreign actions and exemptions increasing cost volatility
- • Most updated regulatory risk: FDA leadership loss and funding cuts raising timing and approval uncertainties for drug applications and clinical guidance
- • Legal risk: $331.3M total indebtedness limits cash flow and could trigger defaults if covenants breached, affecting operations and refinancing capacity
- • Operational risk: reliance on gedatolisib API supply affected by tariffs, raising material costs and operational execution risks amid global trade tensions
- • Financial risk: $220M additional term loans available contingent on milestones, increasing leverage and contingent future debt obligations impacting liquidity
Celcuity Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$44M
▼ -47.0% YoY▲ +3.2% QoQ
ROE
-37.5%
Total Assets
$476M
EPS (Diluted)
$-0.91
▼ -30.0% YoY▲ +12.5% QoQ
Operating Cash Flow
-$45M
▼ -118.0% YoY▼ -23.8% QoQ
Source: XBRL data from Celcuity Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Celcuity Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.